BFK — Pharmesis International Balance Sheet
0.000.00%
- SG$18.39m
- SG$20.49m
- CNY67.65m
Annual balance sheet for Pharmesis International, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 15.2 | 14 | 19.7 | 9.48 | 4.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 12.7 | 14.2 | 12.9 | 8.31 | 37.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 37 | 37.1 | 44.2 | 33.3 | 56.5 |
Net Property, Plant And Equipment | 51.8 | 53.1 | 51.3 | 50.2 | 56.6 |
Net Goodwill | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 91.3 | 92.7 | 97.9 | 85.9 | 116 |
Accounts Payable | |||||
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 32.4 | 30.8 | 39.6 | 30.6 | 53.6 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Liabilities | 35 | 35.2 | 44 | 34.8 | 54.3 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 56.3 | 57.5 | 53.9 | 51.1 | 61.6 |
Total Liabilities & Shareholders' Equity | 91.3 | 92.7 | 97.9 | 85.9 | 116 |
Total Common Shares Outstanding |